Halozyme Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 373
- Market Cap
- $8B
- Website
- http://www.halozyme.com
- Introduction
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and a...
Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00369187
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT00318643
- Locations
- 🇺🇸
MedResearch, La Mesa, California, United States
🇺🇸Advanced Research Institute, New Port Richey, Florida, United States
🇺🇸BCG Oncology, Phoenix, Arizona, United States
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-04-06
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00311519
- Locations
- 🇺🇸
West Coast Clinical Trials, Long Beach, California, United States
© Copyright 2024. All Rights Reserved by MedPath